Take a look at the full article tab on this link of lunatick's. Under Tumor Cell-based Vaccines, authors reference clinical trial 5968 (L) but do not ref name of vaccine. Typing with one finger here so can't grab section. Then author references rindopepimut (celldex) by name twice in article.
Says the 68 trial has a "low accrual rate, illustrating the complexity of this approach" while the celldex trial has an "excellent accrual".
News 
Market Data 
Discover 
